News
DRMA
1.250
-3.85%
-0.050
Weekly Report: what happened at DRMA last week (0406-0410)?
Weekly Report · 2d ago
Dermata Therapeutics announces annual shareholder meeting webcast
Reuters · 04/07 10:01
Weekly Report: what happened at DRMA last week (0330-0403)?
Weekly Report · 04/06 10:22
Dermata receives notice of acceptance of Australian patent application
TipRanks · 04/02 12:39
Dermata Therapeutics Secures Australian Patent Acceptance For Bioneedle System In Dermal Fillers
Benzinga · 04/02 12:38
Dermata says Australian patent application for topical dermal fillers accepted for Bioneedle system
Reuters · 04/02 12:32
Dermata Therapeutics price target lowered to $4 from $10 at Maxim
TipRanks · 04/01 12:35
Weekly Report: what happened at DRMA last week (0323-0327)?
Weekly Report · 03/30 10:22
Dermata Therapeutics GAAP EPS of -$8.16
Seeking Alpha · 03/27 14:16
Dermata Therapeutics FY2025 net loss narrows 38.48% to $(7.6) million; operating expenses drop 37.87% to $7.8 million
Reuters · 03/26 21:18
Dermata Therapeutics FY2025 net loss narrows 38.5% to $7.6 million; cash and cash equivalents climb 138% to $8 million
Reuters · 03/26 21:17
Weekly Report: what happened at DRMA last week (0316-0320)?
Weekly Report · 03/23 10:19
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 03/20 17:06
Dermata Shares Rise After USPTO Issues Patent Notice Of Allowance
Benzinga · 03/20 14:39
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 03/20 12:05
Why Planet Labs Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Benzinga · 03/20 08:51
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 03/19 21:05
UPDATE: Dermata Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS"
Benzinga · 03/19 20:27
Dermata Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS"
Benzinga · 03/19 20:00
Weekly Report: what happened at DRMA last week (0309-0313)?
Weekly Report · 03/16 10:18
More
Webull provides a variety of real-time DRMA stock news. You can receive the latest news about Dermata Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About DRMA
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.